Bruce Okoye
The Royal Marsden NHS Foundation Trust
6 Papers
26 Citations
Bruce Okoye is an academic researcher from The Royal Marsden NHS Foundation Trust. The author has contributed to research in topics: Biopsy & Internal medicine. The author has an hindex of 4, co-authored 6 publications.
Chat about Author
Papers
Nephron Sparing Surgery (NSS) for Unilateral Wilms Tumor (UWT): The SIOP 2001 Experience
Jim C. H. Wilde,Daniel C. Aronson,Beata Sznajder,Harm van Tinteren,Mark Powis,Bruce Okoye,Giovanni Cecchetto,Georges Audry,Joerg Fuchs,Dietrich von Schweinitz,Hugo A. Heij,Norbert Graf,Christophe Bergeron,Kathy Pritchard-Jones,Marry M. van den Heuvel-Eibrink,Modesto Carli,Foppe Oldenburger,Bengt Sandstedt,Jan de Kraker,Jan Godzinski +19 more
TL;DR: Inventory of the current SIOP NSS‐experience for polar or peripherally non‐infiltrating tumors for Nephron Sparing surgery for unilateral Wilms tumors.
103
Evaluation of needle biopsy as a potential risk factor for local recurrence of Wilms tumour in the SIOP WT 2001 trial.
Sabine Irtan,Harm van Tinteren,Norbert Graf,Marry M. van den Heuvel-Eibrink,Hugo A. Heij,Christophe Bergeron,Beatriz de Camargo,T Acha,Filippo Spreafico,Gordan M. Vujanic,Mark Powis,Bruce Okoye,Jim C. H. Wilde,J. Godzinski,Kathy Pritchard-Jones +14 more
TL;DR: This post hoc analysis provides some reassurance that needle biopsy is not an independent adverse factor for either local recurrence or survival after adjustment for all relevant risk factors.
32
Solid tumours of childhood
TL;DR: Determining the best time for surgical intervention in relation to the response to chemotherapy can be essential for achieving good outcomes in the care of children with solid tumours.
15
Treatment of High Risk Sertoli–Leydig Cell Tumors of the Ovary Using a Gonadotropin Releasing Hormone (GnRH) Analog
Harsha Prasada Lashkari,Ruth Nash,Assunta Albanese,Bruce Okoye,Robert P. Millar,Robert P. Millar,Robert P. Millar,Kathy Pritchard-Jones,Kathy Pritchard-Jones +8 more
TL;DR: The use of GnRH analog to lower gondadotropin and potentially directly inhibit the tumors through expressed GnRH receptors was exploited to reduce the risk of recurrence and to use it as maintenance antitumor therapy for 2 years after completion of chemotherapy.